EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

A systematic literature review and meta‐analysis of real‐world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes

Johannes Pöhlmann iD, Jayne Smith-Palmer iD, Erik H Serné iD, Anna-Kaisa Tuomaala iD, Johan Jendle iD, Pratik Choudhary iD, Emanuele Bosi iD, Viswanathan Mohan iD, Tim van den Heuvel iD, Ohad Cohen iD, Richard F Pollock iD

Diabetes, Obesity and Metabolism · 2026-01 · 28 (S1) · 13-34

DOI: 10.1111/dom.70161 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.10.2025. Verfasst von Johannes Pöhlmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Covalence Research, Harpenden, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Insulin, Hypoglycemic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medtronic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Automated insulin delivery (AID) is part of the standard of care for type 1 diabetes (T1D), but real‐world evidence (RWE) comparing AID systems remains limited. A systematic review and meta‐analysis was conducted for outcomes across commercially available AID systems in real‐world settings. Materials and Methods PubMed and Embase were searched to March 2025 for RWE studies of commercial AID systems in ambulatory people with T1D. Eligible studies had n ≥ 250 with ≥10 days of continuous glucose monitoring data. Main outcomes were time in range (TIR) and glycated haemoglobin (HbA1c). Random‐effects meta‐analyses with AID system as moderator were performed, including scenario analyses by age and optimal device settings.

Results

Thirty‐six records covering 34 studies with 635 463 users were included. Studies evaluated MiniMed™ 780G ( n = 16), Control‐IQ™ ( n = 9), MiniMed™ 670G ( n = 6), and other systems (≤3 studies each). Meta‐analysis demonstrated frequently statistically significant between‐system differences in TIR, ranging from 60.1% (95% confidence interval [CI] 54.0 to 65.9) for Omnipod® 5 to 73.9% (95% CI 72.3 to 75.5) for MiniMed 780G. For HbA1c, estimates ranged from 6.5% (95% CI 5.4 to 7.7) for Loop to 7.0% (95% CI 6.7 to 7.4) for MiniMed 780G, although differences were not significant. Significant residual heterogeneity was observed. Age was an important effect modifier, with younger users experiencing less favourable outcomes. Optimal device settings improved glycaemic outcomes.

Conclusions

RWE demonstrated differences in glycaemic outcomes, including TIR, between commercially available AID systems. User age influenced outcomes for all systems. Results must be interpreted cautiously given challenges and potential biases with RWE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin Infusion SystemsInsulinHypoglycemic AgentsHumansGlycated HemoglobinBlood GlucoseBlood Glucose Self-Monitoring

Stichwörter der Autor:innen

advanced hybrid closed loopautomated insulin deliveryglycaemic outcomesmeta‐analysissystematic literature review

Substanzen

InsulinHypoglycemic AgentsGlycated HemoglobinBlood Glucose

Autor:innen und Institutionen

  • Covalence Research, Harpenden, UK.
  • Department of Internal Medicine, Amsterdam UMC, Amsterdam, Netherlands.
  • Department of Gynaecology and Paediatrics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Diabetes Endocrinology and Metabolism Research Center, Örebro University, Örebro, Sweden.
  • Department of Population Health Sciences, King's College London, London, UK.
  • Department of Population Health Sciences, University of Leicester, Leicester, UK.

ORCID-Profile: Johannes Pöhlmann, Jayne Smith-Palmer, Erik H Serné, Anna-Kaisa Tuomaala, Johan Jendle, Pratik Choudhary, Emanuele Bosi, Viswanathan Mohan, Tim van den Heuvel, Ohad Cohen, Richard F Pollock

Förderung

  • Medtronic

Zitieren

APA

Pöhlmann, J., Smith-Palmer, J., Serné, E. H., Tuomaala, A. K., Jendle, J., Choudhary, P., Bosi, E., Mohan, V., van den Heuvel, T., Cohen, O., & Pollock, R. F. (2026). A systematic literature review and meta‐analysis of real‐world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes. Diabetes, Obesity and Metabolism, 28(S1), 13-34. https://doi.org/10.1111/dom.70161

Vancouver

Pöhlmann J, Smith-Palmer J, Serné EH, Tuomaala AK, Jendle J, Choudhary P, et al. A systematic literature review and meta‐analysis of real‐world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes. Diabetes, Obesity and Metabolism. 2026;28(S1):13-34. doi:10.1111/dom.70161

BibTeX
@article{Phlmann2026,
  author = {Pöhlmann, Johannes and Smith-Palmer, Jayne and Serné, Erik H and Tuomaala, Anna-Kaisa and Jendle, Johan and Choudhary, Pratik and Bosi, Emanuele and Mohan, Viswanathan and van den Heuvel, Tim and Cohen, Ohad and Pollock, Richard F},
  title = {A systematic literature review and meta‐analysis of real‐world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {S1},
  pages = {13--34},
  doi = {10.1111/dom.70161}
}
Kostenlos starten →